Scarica l'app Stockscreener
4.63
3.74%
-0.18
Dopo l'orario di chiusura:
4.58
-0.05
-1.08%
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It (NASDAQ:VNDA) - Seeking Alpha
Capitals Announce Fan Initiatives Surrounding Capitals Opening Night Presented by Vanda Pharmaceuticals - NHL.com
Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug - Benzinga
Vanda Pharmaceuticals (VNDA) Reports Positive Phase III Results for HETLIOZ in DSWPD - GuruFocus
Vanda Pharmaceuticals says Phase III HETLIOZ study met sleep endpoint - Mugglehead Investment Magazine
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Stocktwits
Why is Vanda Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
Vanda Pharmaceuticals Announces Positive Phase III Results For Hetlioz®(Tasimelteon) In Delayed Sleep-Wake Phase Disorder - TradingView
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder - PR Newswire
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
Teva, Apotex Don't Infringe Sleep Drug Patents, Judge Finds - Law360
Teva, Apotex Beat Vanda Patent Claims Over Hetlioz Sleep Drug - Bloomberg Law News
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
VNDA Initiates Coverage On Oppenheimer -- Rating Outperform with $10.00 Price Target - GuruFocus
Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating - Investing.com
Vanda Pharmaceuticals stock slips as 2025 loss widens - AD HOC NEWS
Vanda Pharmaceuticals at H.C. Wainwright conference: pipeline broadens By Investing.com - Investing.com Canada
VNDA: BYSANTI and NEREUS launches, plus pivotal readouts, set up major growth opportunities ahead - TradingView
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
VNDA: BYSANTI and NEREUS launches, plus pipeline catalysts, set the stage for major revenue growth - TradingView
Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage - Investing.com Canada
VNDA: BYSANTI and NEREUS launches, plus key phase III trials, set the stage for major revenue growth - TradingView
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
Vanda Pharmaceuticals Inc. (VNDA) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
DC’s Vanda Pharmaceuticals Wins EU Orphan Status for Its Rare Skin Disease Drug - BioBuzz
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences - StreetInsider
Four September conferences are planned for Vanda Pharmaceuticals. Two presentations may be accessed live. - Stock Titan
Vanda Pharmaceuticals Inc. (VNDA) Peer Comparison – Compare with Others - valueresearchonline.com
Convert Vanda Pharmaceuticals Inc. (VNDA) to Canadian Dollar (CAD) - Crypto.com
Vanda Pharmaceuticals Mallorca Women's Championships 2026 Scores | Latest Scores & Live Updates – WTA Official - WTA Tennis
Millennium Management Expands Vanda Pharmaceuticals Stake Amid D - GuruFocus
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - PR Newswire
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. - Sahm
Millennium reports 3.38M-share passive stake in Vanda (NASDAQ: VNDA) - Stock Titan
DC Circuit Partially Rejects Vanda’s Fight of Generic Sleep Drug - Bloomberg Law News
Vanda Pharmaceuticals Inc (VNDA) (Q2 2026) Earnings Call Highlig - GuruFocus
Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044 - Pulse 2.0
AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G - Stock Titan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst - MarketBeat
VNDA Reiterated by B. Riley Securities -- Price Target Lowered t - GuruFocus
Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial - MarketBeat
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):